Abstract Body: Introduction: Essential hypertension is characterized by resistance artery remodeling induced by oxidative stress. Most vessels are surrounded by perivascular adipose tissue (PVAT) which regulates vascular tone via release of vasoactive substances. In physiological conditions, PVAT induces an anticontractile effect. In pathological conditions such as hypertension, PVAT exhibit increased oxidative stress resulting in augmented contraction and reduced relaxation. Follistatin, an antioxidant glycoprotein, has been shown to induce adipose tissue browning which is linked to improved vasorelaxation and BP. We hypothesize that follistatin, through ROS inhibition and PVAT browning, lowers BP and improves vessel function in a model of essential hypertension.

Methods: Spontaneously hypertensive rats (SHR) were treated with vehicle or follistatin every other day for 8 weeks. Wistar Kyoto (WKY) rats served as normotensive controls. BP was measured weekly by radiotelemetry. Mesenteric arteries and PVAT were used. KCl-induced smooth muscle contraction was assessed using wire myography. ROS was measured by DHE (dihydroethidium) staining. Vasodilator nitric oxide (NO) bioavailability in PVAT was measured using DAF-2 FM. Protein expression of markers for ROS or PVAT browning was measured by immunohistochemistry.

Results: Follistatin significantly lowered BP in SHRs and restored anticontractile effect of PVAT. Increased ROS in SHR vessels and PVAT were also inhibited. Follistatin inhibited SHR PVAT-induced vascular oxidative stress. SHR PVAT NO bioavailability was increased by acute follistatin treatment via ROS inhibition. Follistatin also increased expression of brown adipose tissue markers in SHR PVAT suggesting PVAT browning.

Limitations: Above studies do not confirm whether PVAT pathology causes hypertension in this model. Vascular dysfunction is an independent risk factor for CVD and our studies do not yet consider effects of follistatin on end-organ damage.

Conclusions: Follistatin lowers BP in SHRs likely via improved vascular and perivascular structure and function. Specifically, follistatin inhibited perivascular ROS, increased NO and induced PVAT browning suggesting improved regulation of vascular function and thus, BP. Future work will utilize proteomic assays to identify novel mediators of follistatin effects on PVAT in the SHR.